Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma: Strong Stock Growth Potential From A Promising New Drug
04:00am, Sunday, 12'th Mar 2023
Verona Pharma's ensifentrine achieved positive results in a Phase 3 study with an indication for COPD. Ensifentrine is also in Phase 2 studies to address asthma and cystic fibrosis.
Verona Pharma plc (VRNA) Q4 2022 Earnings Call Transcript
12:03pm, Tuesday, 07'th Mar 2023
Verona Pharma plc (NASDAQ:VRNA ) Q4 2022 Earnings Conference Call March 7, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Of
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
02:00am, Tuesday, 21'st Feb 2023
LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato
Verona Pharma: Small Biotech Targeting $10Bn COPD Market With A Late Stage Drug
06:01am, Tuesday, 07'th Feb 2023
Verona Pharma is a UK-based biotech with a $1.6Bn market cap developing a phase 3 asset targeting COPD. Ensifentrine is a novel phase 3 inhaled selective dual inhibitor of PDE3 and PDE4 targeting COPD
Verona: Second Successful Phase 3 Moves The Needle Forward
06:25pm, Wednesday, 01'st Feb 2023
Verona Pharma plc's primary endpoint and all key secondary endpoints met in second phase 3 study known as ENHANCE-1; Ensifentrine was used to treat patients with chronic obstructive pulmonary disease.
Verona Pharma: Breathing Deeply Could Bring Great Benefits
02:31am, Friday, 13'th Jan 2023
Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great
Top 10 Stocks For 2023
02:00am, Thursday, 05'th Jan 2023
Expect the unexpected has been a common theme over the past two years as global economies and markets reel from a pandemic and the war in Ukraine. June 2022 posted some of the worst performance in dec
Why These 7 Healthcare Stocks Could Soar in 2023
07:22am, Monday, 02'nd Jan 2023
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at
4 Drug Stocks That More Than Doubled This Year
10:32am, Friday, 30'th Dec 2022
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going
10:33am, Thursday, 22'nd Dec 2022
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma PLC American Depositary Share (VRNA) could be a great choice. It is one of the several stocks tha
7 Drug Stocks That Will Soar in 2023
06:00am, Thursday, 22'nd Dec 2022
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves
Why Is Verona Pharma (VRNA) Stock Up 34% Today?
10:57am, Tuesday, 20'th Dec 2022
Verona Pharma (NASDAQ: VRNA ) stock is rising higher on Tuesday after the company released results from a Phase 3 clinical trial. The big news here is the company's Phase 3 ENHANCE-1 trial meeting its
Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High
09:19am, Tuesday, 20'th Dec 2022
Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high. The post Top-Notch Verona Pharma Scores A Win In COPD — And H
Verona Pharma's stock jumps 39% after sharing positive data for its COPD drug
08:18am, Tuesday, 20'th Dec 2022
U.S.-listed shares of Verona Pharma Plc VRNA, +2.74% rallied about 39% in premarket trading on Tuesday after the company said a Phase 3 clinical trial evaluating nebulized ensifentrine as a treatment
Lucid Is Revving Up, but This Nasdaq Stock Is Jumping Even More
08:14am, Tuesday, 20'th Dec 2022
Investors hoped for a rebound in the stock market, but they might have to settle for gains in these two stocks.
